{"groups":[{"description":"Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks","id":"FG000","title":"Placebo/FOLFIRI"},{"description":"Participants with Metastatic Colorectal Cancer administered 4 mg/kg of Aflibercept, followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks","id":"FG001","title":"Aflibercept/FOLFIRI"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"163"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"437"},{"groupId":"FG001","numSubjects":"305"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}],"type":"poor compliance to protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"20"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}],"type":"Consent Withdrawn"},{"reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"77"}],"type":"Subject request"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"}],"type":"Metastatic surgery"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Unauthorized procedure"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}],"type":"Randomized but not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}],"type":"Missed visit window"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Planning surgery"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"14"}],"type":"Ongoing Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"614"},{"groupId":"FG001","numSubjects":"612"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"609"},{"groupId":"FG001","numSubjects":"607"}],"type":"TREATED"},{"achievements":[{"comment":"Treated participants excluding 4 who received at least 1 dose of Aflibercept","groupId":"FG000","numSubjects":"605"},{"comment":"Treated participants including 4 from Placebo/FOLFIRI who received at least 1 dose of Aflibercept","groupId":"FG001","numSubjects":"611"}],"type":"SAFETY POPULATION"},{"achievements":[{"comment":"Participants continuing treatment on the cutoff date of the final analysis","groupId":"FG000","numSubjects":"11"},{"comment":"Participants continuing treatment on the cutoff date of the final analysis","groupId":"FG001","numSubjects":"14"}],"type":"ONGOING TREATMENT"},{"achievements":[{"comment":"Participants met treatment discontinuation criteria or were ongoing treatment on the cutoff date","groupId":"FG000","numSubjects":"0"},{"comment":"Participants met treatment discontinuation criteria or were ongoing treatment on the cutoff date","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"614"},{"groupId":"FG001","numSubjects":"612"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between 19 November 2007 and 16 March 2010, 614 participants were randomized to the placebo arm and 612 participants were randomized to the aflibercept arm."}